High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
62.62B
+3.55%
7.121
+5.96%
64.22B
+0.82%
7.919
+5.45%
65.76B
+0.11%
7.940
+19.58%
Estimates Revision
The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by -1.89%.
Revenue Estimates for FY2025
Revise Upward
+1.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.1%
In Past 3 Month
Stock Price
Go Down
-1.89%
In Past 3 Month
20 Analyst Rating
0Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 380.79 USD with a low forecast of 341.00 USD and a high forecast of 407.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
4 Hold
0 Sell
Strong Buy
0Current: 314.350
Low
341.00
Averages
380.79
High
407.00
0Current: 314.350
Low
341.00
Averages
380.79
High
407.00
Barclays
Overweight
maintain
$382 -> $385
2025-06-02
Reason
Barclays
Price Target
$382 -> $385
2025-06-02
maintain
Overweight
Reason
Barclays raised the firm's price target on Cigna to $385 from $382 and keeps an Overweight rating on the shares. Following Q1 earnings and "several negative data points" around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Guggenheim
Guggenheim
Buy
maintain
$928 -> $936
2025-05-23
Reason
Guggenheim
Guggenheim
Price Target
$928 -> $936
2025-05-23
maintain
Buy
Reason
Guggenheim raised the firm's price target on Eli Lilly (LLY) to $936 from $928 and keeps a Buy rating on the shares after detailing how the firm is thinking about GLP1 market dynamics through the remainder of the year. Both Lilly and Novo Nordisk (NVO) have stated their strong preference for open access and the firm notes as part of the updated agreement with Express Scripts and Cigna's (CI) Evernorth announced Wednesday that the companies maintained open access through the end of 2026 for Wegovy and Zepbound with prices "in line with Lilly's normal price concessions," per the company. Overall, the firm believes both companies are positioned to meet 2025 guidance, although it continues to assume Novo will be at the low end of guidance with material risk to sales and earnings in 2026-27 if GLP1 prescriptions don't accelerate.
Citi
Sell
maintain
$30
2025-05-22
Reason
Citi
Price Target
$30
2025-05-22
maintain
Sell
Reason
Citi keeps a Sell rating on Hims & Hers (HIMS) with a $30 price target after Cigna's (CI) Evernorth announced it is launching a new benefit option that caps patient out-of-pocket costs for Wegovy and Zepbound at $200 per month. This is lower than the cash pay price for Wegovy offered through NovoCare and Tirzepatide Vials offered through LillyDirect, the analyst tells investors in a research note. Citi says the Evernorth's offering also has the benefit of counting out-of-pocket costs towards the patients' annual deductible and simplifying prior authorization. The firm believes this will be a "slight headwind" to Hims & Hers' newly announced NovoCare partnership where patients get access to Wegovy and ongoing clinician and nutritional support for as little as $599 per month. The direct-to-consumer platforms have benefited from employer reluctance to cover GLP-1s for weight loss due to prohibitive costs, but Evernorth's offering may accelerate employer coverage adoption, contends Citi.
Truist
David MacDonald
Buy
maintain
$385 -> $405
2025-05-12
Reason
Truist
David MacDonald
Price Target
$385 -> $405
2025-05-12
maintain
Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Cigna to $405 from $385 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Baird
Michael Ha
Buy
Maintains
$388 → $362
2025-04-15
Reason
Baird
Michael Ha
Price Target
$388 → $362
2025-04-15
Maintains
Buy
Reason
Truist Securities
David Macdonald
Strong Buy
Maintains
$375 → $385
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$375 → $385
2025-04-11
Maintains
Strong Buy
Reason
Truist raised the firm's price target on Cigna to $385 from $375 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cigna Group (CI.N) is 10.10, compared to its 5-year average forward P/E of 10.92. For a more detailed relative valuation and DCF analysis to assess Cigna Group 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
10.92
Current PE
10.10
Overvalued PE
11.97
Undervalued PE
9.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
9.18
Current EV/EBITDA
8.19
Overvalued EV/EBITDA
9.94
Undervalued EV/EBITDA
8.41
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.42
Current PS
0.32
Overvalued PS
0.47
Undervalued PS
0.37
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
CI News & Events
Events Timeline
(ET)
2025-06-20
12:19:14
Health insurers to promise improved pre-approval process, WSJ reports
2025-06-16 (ET)
2025-06-16
16:31:35
Senate Republicans abandon Medicare cost cuts, Bloomberg reports
2025-06-05 (ET)
2025-06-05
14:06:21
Senate Republicans consider Medicare spending cuts, Bloomberg says
Sign Up For More Events
Sign Up For More Events
News
Preview
7.0
06-21WSJExclusive | Health Insurers to Promise Changes to Preapproval Process That Drew Backlash
Preview
7.0
06-20BenzingaMark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Preview
8.0
06-18NASDAQ.COMInteresting CI Put And Call Options For August 15th
Sign Up For More News
People Also Watch
FAQ
What is Cigna Group (CI) stock price today?
What is Cigna Group (CI)'s business?
What is the price predicton of CI Stock?
What is Cigna Group (CI)'s revenue for the last quarter?
What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cigna Group (CI)'s fundamentals?
How many employees does Cigna Group (CI). have?